523 related articles for article (PubMed ID: 29748353)
1. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E; Giugliano RP
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003998. PubMed ID: 29748353
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Bergmark BA; Kamphuisen PW; Wiviott SD; Ruff CT; Antman EM; Nordio F; Kuder JF; Mercuri MF; Lanz HJ; Braunwald E; Giugliano RP
Circulation; 2019 Nov; 140(22):1792-1801. PubMed ID: 31597460
[TBL] [Abstract][Full Text] [Related]
3. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ; Magnuson EA;
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862934
[TBL] [Abstract][Full Text] [Related]
4. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA;
Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013
[TBL] [Abstract][Full Text] [Related]
6. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
Xu H; Ruff CT; Giugliano RP; Murphy SA; Nordio F; Patel I; Shi M; Mercuri M; Antman EM; Braunwald E
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908401
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
8. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
Nelson SE; Giugliano RP; Antman EM; Park JG; Norden AD; Rost NS; Silverman S; Singhal AB; Lanz HJ; Braunwald E; Ruff CT;
J Clin Neurosci; 2021 Apr; 86():294-300. PubMed ID: 33446422
[TBL] [Abstract][Full Text] [Related]
9. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
[TBL] [Abstract][Full Text] [Related]
10. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
11. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
[TBL] [Abstract][Full Text] [Related]
12. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Steffel J; Ruff CT; Yin O; Braunwald E; Park JG; Murphy SA; Connolly S; Antman EM; Giugliano RP
J Am Coll Cardiol; 2021 Mar; 77(9):1197-1207. PubMed ID: 33663737
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
Nicolau AM; Corbalan R; Nicolau JC; Ruff CT; Zierhut W; Kerschnitzki M; Duris T; Juul-Möller S; Voitk J; Trevisan M; Nordio F; Antman EM; Giugliano RP
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):167-175. PubMed ID: 31687762
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
Magnuson EA; Vilain K; Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ;
Am Heart J; 2015 Dec; 170(6):1140-50. PubMed ID: 26678636
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.
Wilkinson C; Wu J; Searle SD; Todd O; Hall M; Kunadian V; Clegg A; Rockwood K; Gale CP
BMC Med; 2020 Dec; 18(1):401. PubMed ID: 33357217
[TBL] [Abstract][Full Text] [Related]
18. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Zelniker TA; Ruff CT; Wiviott SD; Blanc JJ; Cappato R; Nordio F; Mercuri MF; Lanz H; Antman EM; Braunwald E; Giugliano RP
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):176-185. PubMed ID: 30039978
[TBL] [Abstract][Full Text] [Related]
19. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin.
Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
J Cardiovasc Electrophysiol; 2018 Jun; 29(6):835-843. PubMed ID: 29533476
[TBL] [Abstract][Full Text] [Related]
20. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
